Jade Biosciences, Inc.
No enriched coverage for $JBIO in the last 7 days.
No SEC Form 4 filings for $JBIO in the last 30 days.
See all $JBIO insider activity →BTIG reiterated a Buy rating on Jade Biosciences with a $77 price target, implying a 431% upside from the Oct 26 close of $14.50. The target is based on strong clinical data for JADE101, showing a 70% reduction in IgA levels, and rapid clinical trial advancements, including a Phase 3 trial expected in 4Q26.
Jade Biosciences (JBIO) delays its Phase 3 trial for JADE101 to Q4 2026, citing disciplined execution. The company presented trial data at ASN Kidney Week 2026 and expects Phase 2 interim data in Q2 2027. Jade focuses on autoimmune disease therapies, including IgA nephropathy treatment.
HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.
Recent JBIO coverage spans financial news, earnings and technology.
BTIG reiterated a Buy rating on Jade Biosciences with a $77 price target, implying a 431% upside from the Oct 26 close of $14.50. The target is based on strong clinical data for JADE101, showing a 70% reduction in IgA levels, and rapid clinical trial advancements, including a Phase 3 trial expected in 4Q26.
Positive clinical trial initiation news likely lifts JBIO.
HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.
Positive preclinical data may lift JBIO as investors anticipate upcoming Phase 1 trial.
The trial initiation is a key milestone that could lift the stock if early data are positive.
AlphAI scores every news story that mentions JBIO with an AI model for sentiment and relevance, and aggregates insider trades from Jade Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG reiterated a Buy rating on Jade Biosciences with a $77 price target, implying a 431% upside from the Oct 26 close of $14.50. The target is based on strong clinical data for JADE101, showing a 70% reduction in IgA levels, and rapid clinical trial advancements, including a Phase 3 trial expected in 4Q26.
2 min readJade Biosciences (JBIO) delays its Phase 3 trial for JADE101 to Q4 2026, citing disciplined execution. The company presented trial data at ASN Kidney Week 2026 and expects Phase 2 interim data in Q2 2027. Jade focuses on autoimmune disease therapies, including IgA nephropathy treatment.
2 min readHC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.
2 min readWedbush reiterated an Outperform rating and $47 price target for Jade Biosciences (JBIO) after positive preclinical data for JADE301. The stock is up 54% over the past year. Analysts expect key data readouts in 2027. Jade Biosciences has no debt and a strong cash position. Multiple analysts have raised price targets and maintained positive ratings.
2 min readJade Biosciences (JBIO) is advancing JADE301, an investigational antibody, toward a Phase 1 trial for dermatomyositis after preclinical studies showed it selectively blocks IFN-Beta. The drug demonstrated high potency and extended half-life, with plans for a trial in Q4 2026. JBIO stock closed at $14.18, down 1.18%.
2 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating autoimmune disease
2 min readJade Biosciences (JBIO) reported Q2 2026 net loss of $55.8M and cash, cash equivalents and investments of $461.2M as of June 30, 2026, saying it funds operations into Q4 2028. R&D was $50.1M and G&A $8.9M. The company advanced JADE101 to Phase 2/3 and updated progress on JADE201 and JADE301.
1 min readJade Biosciences (NASDAQ: JBIO) reported net losses of $55.8M for Q2 2026 and $96.1M for the first half of 2026, versus $32.1M and $70.3M a year earlier. Cash and investments totaled $461.2M at June 30, 2026 after a June equity financing. The company advanced JADE101, JADE201, and JADE301.
6 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update • Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy
6 min readJade Biosciences reported that its Q2 net loss widened as costs increased, according to the company. The update highlights higher operating expenses affecting profitability. Investors may monitor the cost trajectory and future funding needs as the company reports ongoing quarterly results.
1 min read
